Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, double-dummy, placebo and active-controlled, three-way crossover study to evaluate the safety, tolerability and efficacy of 28-day inhaled CHF 6001 DPI (1200microgrammes daily) in subjects with COPD

Next Previous
X
Search
Trial Profile

A randomised, double-blind, double-dummy, placebo and active-controlled, three-way crossover study to evaluate the safety, tolerability and efficacy of 28-day inhaled CHF 6001 DPI (1200microgrammes daily) in subjects with COPD

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tanimilast (Primary) ; Roflumilast
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Chiesi Farmaceutici

    • Most Recent Events

    • 26 Mar 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 21 Nov 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01730404).
    • 20 Oct 2012 Planned End Date 1 Aug 2013 added as reported by EudraCT.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top